NeuroBo Pharmaceuticals (Nasdaq: NRBO), a clinical-stage biotechnology company focused on cardiometabolic diseases, has raised around $70 million through a private share placement. 26 June 2024
Following on from warnings made by national regulators and Novo Nordisk, the World Health Organization (WHO) has become the latest to warn about falsified semag 21 June 2024
US Senator Bernie Sanders, chairman of the Senate Committee on Health, Education, Labor and Pensions (HELP), has announced that members will vote next week on w 12 June 2024
The race to secure market share for GLP-1 agonists continues to develop, with Eli Lilly revealing more promising results for its option, tirzepatide. 6 June 2024
New research published in Nature Communications shows another potential application for GLP-1 agonists, adding to established benefits in type 2 diabetes, obesi 30 May 2024
Already a blockbuster diabetes and weight loss drug sold by Novo Nordisk under the brand names Ozempic, Rybelsus and Wegovy, semaglutide’s standing has been fur 24 May 2024
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.